Circulating MOTS-c in Humans: Age, Exercise, Obesity and Assay Limits

RESEARCH · MOTS-C · HUMAN OBSERVATIONAL

Circulating MOTS-c in Humans: Age, Exercise, Obesity and Assay Limits

MOTS-c is a 16-amino-acid mitochondrial-encoded peptide. Our overview, What is MOTS-c? A Research Overview, covers discovery biology; a later article addresses lyophilized peptide stability. This piece focuses on what peer-reviewed human observational work reports about circulating or endogenous MOTS-c — age, exercise, obesity and insulin resistance — and why measurement itself is still unsettled. PurixLab’s MOTS-C 10mg is a research material for laboratory research use only; observational plasma associations are not claims about any vial.

From discovery biology to human blood

Lee and colleagues identified MOTS-c as a mitochondrial 12S rRNA short ORF encoding a 16-amino-acid peptide that regulates insulin sensitivity and metabolic homeostasis, with skeletal muscle as a primary target organ and AMPK activation downstream of folate-cycle effects; mouse work showed protection against age- and diet-related insulin resistance [1]. That preclinical map motivated human blood measurements. Circulating levels are usually estimated by immunoassay; absolute values differ dramatically across kits and cohorts, which already hints that “MOTS-c concentration” is method-dependent.

Obesity, insulin resistance and mixed directions

In a Chinese paediatric case-control study (40 obese versus 57 controls), circulating MOTS-c was lower in the obese group overall (472.61 ± 22.83 versus 561.64 ± 19.19 ng/mL). The reduction was clear in males (465.26 ± 24.53 versus 584.07 ± 21.18 ng/mL) but not in females, and in males MOTS-c correlated inversely with BMI, waist measures, fasting insulin, HOMA-IR and HbA1c [2]. Another paediatric series (225 obese versus 218 healthy children) likewise found lower serum MOTS-c and lower reactive hyperemia index in the obese group, with MOTS-c mediating part of the BMI–endothelial-function link (mediating-effect ratio 9.12%) [3].

Adult data are less one-directional. In lean versus obese adults (n = 10 per group), Cataldo et al. found similar plasma MOTS-c (0.48 ± 0.16 versus 0.52 ± 0.15 ng/mL) yet correlations with HOMA and Matsuda indices that held mainly in lean participants [4]. A larger adult comparison (48 with BMI ≥ 30 kg/m² versus 37 normal-BMI) reported no significant MOTS-c difference (14.33 ± 3.76 versus 13.67 ± 3.44 pg/mL) but a positive correlation with HOMA-IR, with age and HOMA-IR as regression predictors [5]. By contrast, adults scheduled for bariatric surgery showed higher circulating MOTS-c than lean controls (273 ± 56 versus 223 ± 50 pg/mL); BMI and HOMA-IR independently predicted higher levels, with a biphasic HOMA-IR relationship rising sharply above roughly 6.6, and MOTS-c unchanged 6 months after surgery despite BMI improvement [6]. In MAFLD, MOTS-c was lower than in healthy controls and lower still when metabolic syndrome was present, and it correlated inversely with NFS, FIB-4 and metabolic-syndrome components [7].

Exercise and endothelial context

Reynolds et al. reported that exercise induces endogenous MOTS-c expression in human skeletal muscle and in circulation, framing the peptide as an exercise-linked mitochondrial signal (mouse performance data in that paper are separate from the human exercise observation) [8]. In a randomised acute-exercise comparison, endurance exercise (45 minutes cycling at 70% of estimated VO2max) significantly raised circulating humanin and showed a trend for MOTS-c, whereas resistance exercise did not; resting HN correlated with MOTS-c and with age, but MDPs did not correlate with VO2max or strength [9]. In patients undergoing angiography without structural coronary lesions, aortic plasma MOTS-c was lower with coronary endothelial dysfunction than with normal acetylcholine responses (p = 0.007) and correlated positively with microvascular and epicardial endothelial function [10].

Assay limits: ELISA versus mass spectrometry

Ramanjaneya et al. used a commercial ELISA during lipid and insulin clamps in PCOS and controls: intralipid raised MOTS-c to 232 ± 124% of basal in controls and 349 ± 206% in PCOS, and insulin then suppressed the lipid-driven rise; eight weeks of moderate exercise training did not change circulating MOTS-c [11]. A doping-control methods paper developed LC/MS for MOTS-c in plasma (LLOD 100 pg/mL) and compared it with ELISA in 20 healthy subjects: ELISA reported 45.9–218.5 ng/mL, but those endogenous levels could not be confirmed by LC/MS [12]. That discrepancy — nanograms per millilitre on immunoassay versus failure to confirm by orthogonal MS, plus other cohorts reporting picograms per millilitre — is a central limitation. Cross-study numeric comparisons of “high” versus “low” MOTS-c should be treated cautiously until assays are harmonised.

What is still unknown

  • Directionality. Some obese cohorts show lower MOTS-c [2,3]; others show similar [4,5] or higher [6] levels.
  • Causality. Cross-sectional and clamp studies do not prove that changing circulating MOTS-c improves human metabolic disease [10,11].
  • Measurement. ELISA–MS disagreement and unit-scale differences across papers remain unresolved [12,6,4].
  • Research vial ≠ plasma peptide. Observational endogenous MOTS-c is not evidence about a lyophilized research material [1].

MOTS-C 10mg at PurixLab

MOTS-C 10mg: a labelled lyophilized research vial with 10mg per vial, C$54 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/mots-c-10mg/.

PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.

In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.

Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.

For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.

View MOTS-C 10mg

Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ

References

  1. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015;21(3):443-54. PubMed 25738459 · PMC4350682 · doi:10.1016/j.cmet.2015.02.009
  2. Du C, Zhang C, Wu W, et al. Circulating MOTS-c levels are decreased in obese male children and adolescents and associated with insulin resistance. Pediatr Diabetes. 2018;. PubMed 29691953 · doi:10.1111/pedi.12685
  3. Luo YH, Xie L, Li JY, et al. Serum MOTS-C Levels are Decreased in Obese Children and Associated with Vascular Endothelial Function. Diabetes Metab Syndr Obes. 2023;16:1013-1020. PubMed 37077579 · PMC10106799 · doi:10.2147/DMSO.S403934
  4. Cataldo LR, Fernández-Verdejo R, Santos JL, et al. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals. J Investig Med. 2018;66(6):1019-1022. PubMed 29593067 · doi:10.1136/jim-2017-000681
  5. Ozkaya DY, Haymana C, Demirci I, et al. MOTS-C levels ın ındividuals with and without obesity and ıts association with ınflammation, insulin resistance and endothelial dysfunction. Arch Endocrinol Metab. 2025;69(5):e250063. PubMed 41004666 · PMC12468430 · doi:10.20945/2359-4292-2025-0063
  6. Yoon SH, Yuan F, Zhu X, et al. Systemic MOTS-c levels are increased in adults with obesity in association with metabolic dysregulation and remain unchanged after weight loss. J Clin Transl Endocrinol. 2026;43:100429. PubMed 41551324 · PMC12807633 · doi:10.1016/j.jcte.2025.100429
  7. Kirik A, Dogru T, Yanik B, et al. The relationship of circulating MOTS-c level with liver fibrosis and metabolic components in patients with metabolic dysfunction-associated fatty liver disease. Eur Rev Med Pharmacol Sci. 2023;27(17):8074-8080. PubMed 37750635 · doi:10.26355/eurrev_202309_33567
  8. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nat Commun. 2021;12(1):470. PubMed 33473109 · PMC7817689 · doi:10.1038/s41467-020-20790-0
  9. von Walden F, Fernandez-Gonzalo R, Norrbom J, et al. Acute endurance exercise stimulates circulating levels of mitochondrial-derived peptides in humans. J Appl Physiol (1985). 2021;131(3):1035-1042. PubMed 34351816 · PMC12854548 · doi:10.1152/japplphysiol.00706.2019
  10. Qin Q, Delrio S, Wan J, et al. Downregulation of circulating MOTS-c levels in patients with coronary endothelial dysfunction. Int J Cardiol. 2018;254:23-27. PubMed 29242099 · doi:10.1016/j.ijcard.2017.12.001
  11. Ramanjaneya M, Jerobin J, Bettahi I, et al. Lipids and insulin regulate mitochondrial-derived peptide (MOTS-c) in PCOS and healthy subjects. Clin Endocrinol (Oxf). 2019;91(2):278-287. PubMed 31066084 · doi:10.1111/cen.14007
  12. Knoop A, Thomas A, Thevis M. Development of a mass spectrometry based detection method for the mitochondrion-derived peptide MOTS-c in plasma samples for doping control purposes. Rapid Commun Mass Spectrom. 2019;33(4):371-380. PubMed 30394592 · doi:10.1002/rcm.8337

Leave a Comment

Your email address will not be published. Required fields are marked *